| Exhibit 99.01 | |
| Press Release |  |
| www.shire.com | |
Notification of major interests in shares
July 29, 2011 - Shire plc (LSE: SHP, NASDAQ: SHPGY)
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Shire plc
| 2. Reason for the notification | State Yes/No |
| An acquisition or disposal of voting rights | Yes |
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |
| An event changing the breakdown of voting rights | |
Other (please specify): |
| 3. Full name of person(s) subject to the notification obligation: | Capital Group International, Inc |
| 4. Full name of shareholder(s) (if different from 3.): | |
5. Date of the transaction (and date on which the threshold is crossed or reached if different): | 27 July 2011 |
| 6. Date on which issuer notified: | 29 July 2011 |
| 7. Threshold(s) that is/are crossed or reached: | Below 4% |
| 8. Notified details: |
A: Voting rights attached to shares
Class/type of shares if possible using the ISIN CODE | Situation previous to the Triggering transaction | Resulting situation after the triggering transaction | ||||||
Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights | ||||
| Direct | Indirect | Direct | Indirect | Direct | Indirect | |||
Ordinary (JE00B2QKY057) | 14,121,202 | 14,121,202 | 13,927,202 | 13,927,202 | 2.4766% | |||
ADR (US82481R1068) | 2,812,773 | 8,438,319 | 2,812,098 | 8,436,294 | 1.5002% | |||
B: Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument | Expiration date | Exercise/Conversion Period/ Date | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
| n/a |
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
| Total (A+B) | |
| Number of voting rights | % of voting rights |
| 22,363,496 | 3.9768% |
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
Number of Shares | Percent of Outstanding | |
Capital Group International, Inc. ("CGII") holdings | 22,363,496 | 3.9768% |
Holdings by CGII Management Companies and Funds: | ||
| • Capital Guardian Trust Company | 17,944,348 | 3.1909% |
| • Capital International Limited | 1,305,341 | 0.2321% |
| • Capital International SÁrl | 513,000 | 0.0912% |
| • Capital International, Inc. | 2,600,807 | 0.4625% |
Proxy Voting:
| 10. Name of the proxy holder: | N/A |
| 11. Number of voting rights proxy holder will cease to hold: | N/A |
| 12. Date on which proxy holder will cease to hold voting rights: | N/A |
| 13. Additional information: | Notification using the total voting rights figures of 562,353,761 |
| 14. Contact name: | Vivien Tan |
| 15. Contact telephone number: | (213) 486 9200 |
Contact at Shire plc: Tony Guthrie, Deputy Company Secretary, +44 1256 894746
For further information please contact:
| Investor Relations | Eric Rojas (erojas@shire.com) | +1 781 482 0999 |
Sarah Elton-Farr (seltonfarr@shire.com) | +44 1256 894157 |
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com
2